Prevalence and prognosis of chronic obstructive pulmonary disease among 8167 middle eastern patients with acute coronary syndrome

Clinical Cardiology

Volumn 33, Issue 4, 2010, Pages 228-235

  Hadi, Hadi A R ^a   Zubaid, Mohammed ^a   Mahmeed, Wael Al ^a   El Menyar, Ayman A ^c   Ridha, Mustafa ^b,d   Alsheikh Ali, Alawi A ^e   Singh, Rajivir ^c   Assad, Nidal ^c   Habib, Khalid Al ^f   Suwaidi, Jassim Al ^c  

^a SHEIKH KHALIFA MEDICAL CITY   (United Arab Emirates)

^b KUWAIT UNIVERSITY   (Kuwait)

^c HAMAD MEDICAL CORPORATION   (Qatar)

^d AL ADAN HOSPITAL   (Kuwait)

^e TUFTS MEDICAL CENTER   (United States)

^f KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; STEROID; THEOPHYLLINE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROL GROUP; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; FIBRINOLYTIC THERAPY; HEART FAILURE; HEART INFARCTION; HIGH RISK PATIENT; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MIDDLE EAST; MORTALITY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDY; ST SEGMENT ELEVATION; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ASPIRIN; CHI-SQUARE DISTRIBUTION; COMORBIDITY; FEMALE; HOSPITAL MORTALITY; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MIDDLE EAST; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REGISTRIES; RISK FACTORS; THROMBOLYTIC THERAPY;

EID: 77950830721     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.20751     Document Type: Article

References (41)

1. Nonkin PM, Dick MM, Baum GL. Myocardial infarction in respiratory insufficiency. Arch Intern Med. 1964;113:42-45.
2. Thomas AJ. Coronary heart disease in the presence of pulmonary disease. Br Heart J. 1958;20:83-91.
3. Bhargava RK, Woolf CR. Relationships between ischemic heart disease and chronic diffuse pulmonary disease. Chest. 1971;59:254-261.
4. Samad IA, Noehren TH. Myocardial infarction in pulmonary emphysema. Chest. 1965;47:26-29.
5. Rees HA, Thomas AJ, Rossiter C. The recognition of coronary heart disease in the presence of pulmonary disease. Br Heart J. 1964;26:233-240.
6. Schlesinger ZV, Goldbourt U, Medalie JH, Neufeld N, Riss E, Oron D. Ischemic heart disease and pulmonary ventilatory function. Isr J Med Sci. 1975;11:308-313.
7. Mapel DW, Dedrick D, Davis K. Trends and cardiovascular comorbidities of COPD patients in the Veterans Administration Medical System, 1991-1999. COPD. 2005;2:35-41. (Pubitemid 40776220)
8. Sidney S, Sorel M, Quesenberry CP Jr, et al. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest. 2005;128:2068-2075. (Pubitemid 41507542)
9. Curkendall SM, DeLuise C, Jones JK, et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan, Canada: cardiovascular disease in COPD patients. Ann Epidemiol. 2006;16:63-70.
10. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation. 2003;107:1514-1519.
11. Antonelli Incalzi R, Fuso L, De Rosa M, et al. Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J. 1997;10:2794-2800.
12. Ridker PM. Evaluating novel cardiovascular risk factors: can we better predict heart attacks? Ann Intern Med. 1999;130:933-937.
13. Danesh J, Whincup P, Walker M, et al. Low-grade inflammation and coronary heart disease: prospective study and updated metaanalyses. BMJ. 2000;321:199-204.
14. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115-126.
15. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107:363-369.
16. Wedzicha JA, Seemungal TA, MacCallum PK, et al. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6. Thromb Haemost. 2000;84:210-215.
17. Black S, Kushner I, Samols D. C-reactive protein. J Biol Chem. 2004;279:48487-48490.
18. Pinto-Plata VM, Müllerova H, Toso JF, et al. C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax. 2006;61:23-28.
19. Broekhuizen R, Wouters EF, Creutzberg EC, et al. Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax. 2006;61:17-22.
20. Dev D, Wallace E, Sankaran R, et al. Value of C-reactive protein measurements in exacerbations of chronic obstructive pulmonary disease. Respir Med. 1998;92:664-667.
21. Dahl M, Vestbo J, Lange P, et al. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175:250-255. (Pubitemid 46203128)
22. ZubaidM, RashedWA, Al Mahmeed W, et al. Management and outcomes ofMiddle Eastern patients admitted with acute coronary syndromes in the Gulf Registry of Acute Coronary Events (Gulf RACE).Acta Cardiol. 2009;64:439-446.
23. El-Menyar A, Zubaid M, Rashed W, et al. Comparison of men and women with acute coronary syndrome in six Middle Eastern countries. Am J Cardiol. 2009;104:1018-1022.
24. Alsheikh-Ali AA, Al-Mallah MH, Al-Mahmeed W, et al. for Gulf RACE Investigators. Heart failure in patients hospitalized with acute coronary syndromes: observations from the Gulf Registry of Acute Coronary Events (Gulf RACE). Eur J Heart Fail. 2009;11:1135-1142.
25. Cannon CP, Battler A, Brindis RG, et al. American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes: a report of the American College of CardiologyTask Force onClinicalData Standards (AcuteCoronary Syndromes Writing Committee). J Am Coll Cardiol. 2001;38: 2114-2130.
26. Al Suwaidi J, Reddan DN, Williams K, et al. for GUSTO-IIb, GUSTO-III, PURSUIT, and PARAGON-A Investigators. Prognostic implications of abnormalities of renal function in patients with acute coronary syndromes. Circulation. 2002;106:974-980.
27. Salisbury AC, Reid KJ, Spertus JA. Impact of chronic obstructive pulmonary disease on post-myocardial infarction outcomes. Am J Cardiol. 2007;99:636-641.
28. Kjøller E, Køber L, Iversen K, Torp-Pedersen C. Trace Study Group. Importance of chronic obstructive pulmonary disease for prognosis and diagnosis of congestive heart failure in patients with acute myocardial infarction. Eur J Heart Fail. 2004;6:71-77.
29. Izbicki G, Ben-Dor I, Shitrit D, et al. The prevalence of coronary artery disease in end-stage pulmonary disease: is pulmonary fibrosis a risk factor? Respir Med. 2009;103:1346-1349.
30. Nishiyama K, Morimoto T, Furukawa Y, et al. Chronic obstructive pulmonary disease-an independent risk factor for long-term cardiac and cardiovascular mortality in patients with ischemic heart disease. Int J Cardiol. 2009; doi:10.1016/j.ijcard.2009.02.010. Available at: http://www.sciencedirect.com.
31. Selvaraj CL, Gurm HS, Gupta R, Ellis SG, Bhatt DL. Chronic obstructive pulmonary disease as a predictor ofmortality in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2005;96:756-759.
32. Berger JS, Sanborn TA, Sherman W, Brown DL. Effect of chronic obstructive pulmonary disease on survival of patientswith coronary heart disease having percutaneous coronary intervention. Am J Cardiol. 2004;94:649-651.
33. Behar S, Panosh A, Reicher-Reiss H, Zion M, Schlesinger Z, Goldbourt U. Prevalence and prognosis of chronic obstructive pulmonary disease among 5,839 consecutive patients with acute myocardial infarction. SPRINT Study Group. Am J Med. 1992;93:637-641.
34. Dziewierz A, Siudak Z, Dykla D, et al. Management and mortality in patients with non-ST-segment elevation vs.ST-segment elevation myocardial infarction. Data from the Malopolska Registry of Acute Coronary Syndromes. Kardiol Pol. 2009;67:115-120.
35. Brekke PH, Omland T, Smith P, et al. Underdiagnosis of myocardial infarction in COPD-Cardiac Infarction Injury Score (CIIS) in patients hospitalised for COPD exacerbation. RespirMed. 2008;102:1243-1247.
36. Nielsen GL, Sørensen HT, Mellemkjoer L, et al. Risk of hospitalization from upper gastrointestinal bleeding among patients taking corticosteroids: a register-based cohort study. Am J Med. 2001;111:541-545.
37. Egred M, Shaw S, Mohammad B, Waitt P, Rodrigues E. Underuse of beta-blockers in patients with ischaemic heart disease and concomitant chronic obstructive pulmonary disease. QJM. 2005;98:493-497.
38. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med. 1998;339:489-497.
39. Olenchock BA, Fonarow GG, PanW, Hernandez A, Cannon CP. Get With The Guidelines Steering Committee. Current use of beta blockers in patients with reactive airway disease who are hospitalized with acute coronary syndromes. Am J Cardiol. 2009;103:295-300.
40. Chen J, Radford MJ, Wang Y, Marciniak TA, Krumholz HM. Effectiveness of beta-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma. J Am Coll Cardiol. 2001;37:1950-1956.
41. Huiart L, Ernst P, Ranouil X, Suissa S. Oral corticosteroid use and the risk of acute myocardial infarction in chronic obstructive pulmonary disease. Can Respir J. 2006;13:134-138.